Trachoma

Lancet

Volumn 362, Issue 9379, 2003, Pages 223-229

  Mabey, David C W ^a   Solomon, Anthony W ^a   Foster, Allen ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL VACCINE; DNA VACCINE; OUTER MEMBRANE PROTEIN; TETRACYCLINE;

ANTIBIOTIC THERAPY; BACTERIAL TRANSMISSION; BLINDNESS; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CLEANING; CLINICAL FEATURE; CONFERENCE PAPER; CORNEA OPACITY; DISEASE ACTIVITY; DISEASE CONTROL; ENVIRONMENTAL CHANGE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFECTION; EYE SURGERY; FACE; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LABORATORY DIAGNOSIS; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; SANITATION; SCAR FORMATION; SCORING SYSTEM; SOCIAL STATUS; TISSUE CULTURE; TRACHOMA; VISUAL IMPAIRMENT; WATER SUPPLY; WORLD HEALTH ORGANIZATION;

EID: 0038783309     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13914-1     Document Type: Conference Paper

References (72)

1. Bryan C.P. The papyrus Ebers: translated from the German version. 1930;Bles, London.
2. Duke-Elder W.S. Textbook of ophthalmology. 1937;Henry Kimpton, London.
3. Jones B.R. The prevention of blindness from trachoma. Trans Ophthalmol Soc UK. 95:1975;16-33.
4. Thylefors B., Negrel A.D., Pararajasegaram R., Dadzie K.Y. Global data on blindness. Bull World Health Organ. 73:1995;115-121.
5. Halberstaedter L., von Prowazek S. Uber Zelleinschlusse parasitarer Natur beim Trachom. Arb Gesumdhamt Berlin. 26:1907;44-47.
6. Tang F.F., Chang H.L., Huang Y.T., Wang K.C. Studies on the etiology of trachoma with special reference to isolation of the virus in chick embryo. Chin Med J. 75:1957;429-447.
7. Collier L.H., Duke-Elder S., Jones B.R. Experimental trachoma produced by cultured virus. Br J Ophthalmol. 42:1958;705-720.
8. Stephens R.S., Kalman S., Lammel C., et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science. 282:1998;754-759.
9. Fehlner-Gardiner C., Roshick C., Carlson J.H., et al. Molecular basis defining human Chlamydia trachomatis tissue tropism: a possible role for tryptophan synthase. J Biol Chem. 277:2002;26893-26903.
10. Barron A.L. Microbiology of chlamydia. 1988;CRC Press, Boca Raton.
11. Grayston J.T., Wang S.P., Yeh L.J., Kuo C.C. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis. 7:1985;717-725.
12. Whittum-Hudson J.A., Taylor H.R., Farazdaghi M., Prendergast R.A. Immunohistochemical study of the local inflammatory response to chlamydial ocular infection. Invest Ophthalmol Vis Sci. 27:1986;64-69.
13. el-Asrar A.M., Van den Oord J.J., Geboes K., Missotten L., Emarah M.H., Desmet V. Immunopathology of trachomatous conjunctivitis. Br J Ophthalmol. 73:1989;276-282.
14. Abu el-Asrar A.M., Geboes K., al-Kharashi S.A., Tabbara K.F., Missotten L. Collagen content and types in trachomatous conjunctivitis. Eye. 12:1998;735-739.
15. Reacher M.H., Pe'er J., Rapoza P.A., Whittum-Hudson J.A., Taylor H.R. T cells and trachoma: their role in cicatricial disease. Ophthalmology. 98:1991;334-341.
16. Zhong G., Liu L., Fan T., Fan P., Ji H. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med. 191:2000;1525-1534.
17. Brunham R.C. Human immunity to Chlamydiae. Stephens R.S. Chlamydia. 1999;211-238 American Society for Microbiology, Washington DC.
18. Wang S.P., Grayston J.T., Alexander E.R. Trachoma vaccine studies in monkeys. Am J Ophthalmol. 63:(suppl):1967;1615-1630.
19. Bailey R., Duong T., Carpenter R., Whittle H., Mabey D. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect. 123:1999;479-486.
20. Bailey R.L., Holland M.J., Whittle H.C., Mabey D.C. Subjects recovering from human ocular chlamydial infection have enhanced lymphoproliferative responses to chlamydial antigens compared with those of persistently diseased controls. Infect Immun. 63:1995;389-392.
21. Holland M.J., Bailey R.L., Hayes L.J., Whittle H.C., Mabey D.C. Conjunctival scarring in trachoma is associated with depressed cell-mediated immune responses to chlamydial antigens. J Infect Dis. 168:1993;1528-1531.
22. Beatty W.L., Belanger T.A., Desai A.A., Morrison R.P., Byrne G.I. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun. 62:1994;3705-3711.
23. Morrison R.P., Lyng K., Caldwell H.D. Chlamydial disease pathogenesis: ocular hypersensitivity elicited by a genus-specific 57-kD protein. J Exp Med. 169:1989;663-675.
24. Peeling R.W., Bailey R.L., Conway D.J., et al. Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma. J Infect Dis. 177:1998;256-259.
25. Beatty W.L., Morrison R.P., Byrne G.I. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev. 58:1994;686-699.
26. Bailey R.L., Hampton T.J., Hayes L.J., Ward M.E., Whittle H.C., Mabey D.C. Polymerase chain reaction for the detection of ocular chlamydial infection in trachoma-endemic communities. J Infect Dis. 170:1994;709-712.
27. Schachter J., West S.K., Mabey D., et al. Azithromycin in control of trachoma. Lancet. 354:1999;630-635.
28. Peeling R., Maclean I.W., Brunham R.C. In vitro neutralization of Chlamydia trachomatis with monoclonal antibody to an epitope on the major outer membrane protein. Infect Immun. 46:1984;484-488.
29. Bailey R.L., Kajbaf M., Whittle H.C., Ward M.E., Mabey D.C. The influence of local antichlamydial antibody on the acquisition and persistence of human ocular chlamydial infection: IgG antibodies are not protective. Epidemiol Infect. 111:1993;315-324.
30. Zhang D., Yang X., Berry J., Shen C., McClarty G., Brunham R.C. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis. 176:1997;1035-1040.
31. Mabey D.C., Bailey R.L., Ward M.E., Whittle H.C. A longitudinal study of trachoma in a Gambian village: implications concerning the pathogenesis of chlamydial infection. Epidemiol Infect. 108:1992;343-351.
32. Bobo L.D., Novak N., Munoz B., Hsieh Y.H., Quinn T.C., West S. Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis. 176:1997;1524-1530.
33. Conway D.J., Holland M.J., Bailey R.L., et al. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect Immun. 65:1997;1003-1006.
34. Conway D.J., Holland M.J., Campbell A.E., et al. HLA class I and II polymorphisms and trachomatous scarring in a Chlamydia trachomatis-endemic population. J Infect Dis. 174:1996;643-646.
35. Dawson C.R., Jones B.R., Tarizzo M.L. Guide to trachoma control in programmes for the prevention of blindness. 1981;World Health Organization, Geneva.
36. Thylefors B., Dawson C.R., Jones B.R., West S.K., Taylor H.R. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 65:1987;477-483.
37. Primary health care level management of trachoma (WHO/PBL/93.33). 1993;World Health Organization, Geneva.
38. Treharne J.D. The community epidemiology of trachoma. Rev Infect Dis. 7:1985;760-764.
39. Ward ME. Classic diagnostic methods: cell culture. Text at: http://www.chlamydiae.com/restricted/docs/labtests/diag_cellcult.htm (accessed Jan 10, 2002).
40. Bobo L., Munoz B., Viscidi R., Quinn T., Mkocha H., West S. Diagnosis of Chlamydia trachomatis eye infection in Tanzania by polymerase chain reaction/enzyme immunoassay. Lancet. 338:1991;847-850.
41. Mabey D, Holland M, Solomon A, et al. The epidemiology of ocular Chlamydia trachomatis infection in a trachoma endemic community determined by quantitative PCR. In: Schachter J, Christiansen G, Clarke IN, et al, eds. Chlamydial infections: Proceedings of the tenth international symposium on human chlamydial infections. Antalya, Turkey, 2002.
42. Holm S.O., Jha H.C., Bhatta R.C., et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ. 79:2001;194-200.
43. Baral K., Osaki S., Shreshta B., et al. Reliability of clinical diagnosis in identifying infectious trachoma in a low-prevalence area of Nepal. Bull World Health Organ. 77:1999;461-466.
44. Dawson C, Munoz B, Shama A, et al. Antibiotic treatment of trachoma in the Egyptian arm of the ACT trial: laboratory testing and clinical examinations. In: Schachter J, Christiansen G, Clarke IN, et al, eds. Chlamydial infections: Proceedings of the tenth international symposium on human chlamydial infections. Antalya, Turkey, 2002.
45. Schachter J, Moncada J. Nucleic acid amplification tests to diagnose Chlamydia trachomatis genital infection: the glass is more than half full. In: Schachter J, Christiansen G, Clarke IN, et al, eds. Chlamydial infections: Proceedings of the tenth international symposium on human chlamydial infections. Antalya, Turkey, 2002.
46. Ward M., Bailey R., Lesley A., Kajbaf M., Robertson J., Mabey D. Persisting inapparent chlamydial infection in a trachoma endemic community in The Gambia. Scand J Infect Dis Suppl. 69:1990;137-148.
47. Faal H., Minassian D., Sowa S., Foster A. National survey of blindness and low vision in The Gambia: results. Br J Ophthalmol. 73:1989;82-87.
48. Malaty R., Zaki S., Said M.E., Vastine D.W., Dawson D.W., Schachter J. Extraocular infections in children in areas with endemic trachoma. J Infect Dis. 143:1981;853.
49. Solomon A, Mabey D, Holland M, et al. Quantification of nasal Chlamydia trachomatis infection in a trachoma endemic area of Tanzania. In: Schachter J, Christiansen G, Clarke IN, et al, eds. Chlamydial infections: Proceedings of the tenth international symposium on human chlamydial infections. Antalya, Turkey, 2002.
50. WHO. Global elimination of blinding trachoma. Geneva, World Health Organization 51st World Health Assembly, Resolution 51.11, 1998. Text at http://who.int/pbd/trachoma/wha51-e.htm (accessed June 13, 2002).
51. Reacher M.H., Munoz B., Alghassany A., Daar A.S., Elbualy M., Taylor H.R. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol. 110:1992;667-674.
52. Reacher M.H., Huber M.J., Canagaratnam R., Alghassany A. A trial of surgery for trichiasis of the upper lid from trachoma. Br J Ophthalmol. 74:1990;109-113.
53. Oliva M.S., Munoz B., Lynch M., Mkocha H., West S.K. Evaluation of barriers to surgical compliance in the treatment of trichiasis. Int Ophthalmol. 21:1997;235-241.
54. West S., Lynch M., Munoz B., Katala S., Tobin S., Mmbaga B.B. Predicting surgical compliance in a cohort of women with trichiasis. Int Ophthalmol. 18:1994;105-109.
55. Courtright P. Acceptance of surgery for trichiasis among rural Malawian women. East Afr Med J. 71:1994;803-804.
56. Bowman R.J., Soma O.S., Alexander N., et al. Should trichiasis surgery be offered in the village? A community randomised trial of village vs. health centre-based surgery. Trop Med Int Health. 5:2000;528-533.
57. Bog H., Yorston D., Foster A. Results of community-based eyelid surgery for trichiasis due to trachoma. Br J Ophthalmol. 77:1993;81-83.
58. Dawson C.R., Schachter J., Sallam S., Sheta A., Rubinstein R.A., Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis. 24:1997;363-368.
59. Tabbara K.F., Abu-el-Asrar A., al-Omar O., Choudhury A.H., al-Faisal Z. Single-dose azithromycin in the treatment of trachoma: a randomized, controlled study. Ophthalmology. 103:1996;842-846.
60. Bailey R.L., Arullendran P., Whittle H.C., Mabey D.C. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 342:1993;453-456.
61. Bowman R.J., Sillah A., Van Dehn C., et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest Ophthalmol Vis Sci. 41:2000;4074-4079.
62. Chern K.C., Shrestha S.K., Cevallos V., et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol. 83:1999;1332-1335.
63. Leach A.J., Shelby-James T.M., Mayo M., et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis. 24:1997;356-362.
64. Somani J., Bhullar V.B., Workowski K.A., Farshy C.E., Black C.M. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 181:2000;1421-1427.
65. Solomon A.W., Akudibillah J., Abugri P., et al. Pilot study of the use of community volunteers to distribute azithromcyin for trachoma control in Ghana. Bull World Health Organ. 79:2001;8-14.
66. Frick K.D., Lietman T.M., Holm S.O., Jha H.C., Chaudhary J.S., Bhatta R.C. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull World Health Organ. 79:2001;201-207.
67. Lietman T., Porco T., Dawson C., Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 5:1999;572-576.
68. West S.K., Congdon N., Katala S., Mele L. Facial cleanliness and risk of trachoma in families. Arch Ophthalmol. 109:1991;855-857.
69. Taylor H.R., West S.K., Mmbaga B.B., et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol. 107:1989;1821-1825.
70. West S., Munoz B., Lynch M., et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet. 345:1995;155-158.
71. Emerson P.M., Lindsay S.W., Walraven G.E., et al. Effect of fly control on trachoma and diarrhoea. Lancet. 353:1999;1401-1403.
72. Planning for the global elimination of trachoma (GET): report of a WHO consultation (WHO/PBL/97.60). 1997;World Health Organization, Geneva.